Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylose SCHEMBL2566013 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL13947312 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL4299987 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL21381544 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL21433656 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL13279394 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL21433655 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL21114379 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL21114394 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Xylose SCHEMBL2725460 | 1.00 | LMNA (0.53) | LMNAL3MBTL1TDP1AKR1B1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082661-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| US-12053482-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2024-08-06 | — | — | US | disclosed |
| EP-4327888-A2 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3782612-B1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2023-08-03 | — | — | US | disclosed |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | CELGENE CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220105118-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-20220079964-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2022-03-17 | — | — | US | disclosed |
| US-9673030-B2 | Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry | EMORY UNIVERSITY (US) | 2017-06-06 | — | — | US | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053482-B2 | Oral formulations of cytidine analogs and methods of use thereof | DCTD, CDA, NT5C2 | LMNA 1285/4885L3MBTL1 2974/4885TDP1 134/4885 |
| US-20230241086-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885L3MBTL1 2974/4885TDP1 134/4885 |
| US-20220105118-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885L3MBTL1 2974/4885TDP1 134/4885 |
| US-20220079964-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885L3MBTL1 2974/4885TDP1 134/4885 |
| US-20250082661-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885L3MBTL1 2974/4885TDP1 134/4885 |
| US-20230255996-A1 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | DCTD, CDA, NT5C2 | LMNA 1285/4885L3MBTL1 2974/4885TDP1 134/4885 |
| US-11571436-B2 | Oral formulations of cytidine analogs and methods of use thereof | DCTD, CDA, NT5C2 | LMNA 1285/4885L3MBTL1 2974/4885TDP1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.